On Mar. 15, 2021, Fulgent Genetics announced that the U.S. Centers for Disease Control and Prevention had awarded the Company a contract to provide genomic sequencing of samples of SARS-CoV-2 on an ongoing basis, leveraging the Companyﾒs Next Generation Sequencing capabilities.